Is there a customised immunosuppressive regimen for patients transplanted with hepatocellular carcinoma?

Journal of Hepatology

Volumn 43, Issue 4, 2005, Pages 577-584

  Majno, Pietro ^a   Giostra, Emiliano ^a   Mentha, Gilles ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CALCINEURIN INHIBITOR; CYCLOSPORIN; CYCLOSPORIN A; EVEROLIMUS; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY;

BLADDER CARCINOMA; BRAIN TUMOR; BREAST CANCER; CANCER RECURRENCE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; MEDICAL ASSESSMENT; NONHUMAN; PRIORITY JOURNAL; REVIEW; THERAPEUTIC ERROR; TRANSPLANTATION TOLERANCE; TREATMENT OUTCOME; TREATMENT PLANNING; TUMOR GROWTH;

CARCINOMA, HEPATOCELLULAR; HUMANS; IMMUNE TOLERANCE; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; LIVER NEOPLASMS; LIVER TRANSPLANTATION;

EID: 24344496612     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2005.07.018     Document Type: Review

References (49)

1. European Liver Transplantation registry. Recipient data: indications for liver transplantation 1988-2003. http://www.eltr.org.
2. Majno G, Joris I. Chapter 20. Antitumor defenses: 909-920. In Cells, tissues and diseases. 2nd ed. Oxford University Press Oxford, New York, 2004.
3. I. Penn The problem of cancer in organ transplant recipients Transplant Sci 4 1994 23 32
4. D.M. Kelly, S. Emre, S.R. Guy, C.M. Miller, M.E. Schwartz, and P.A. Sheiner Liver transplant recipients are not at increased risk for nonlymphoid solid organ tumors Cancer 83 1998 1237 1243
5. M.T. Oruc, A. Soran, A.K. Jain, J.W. Wilson, and J. Fung De novo breast cancer in patients with liver transplantation: University of Pittsburgh's experience and review of the literature Liver Transpl 10 2004 1 6
6. R.F. Saidi, P.S. Dudrick, and M.H. Goldman Colorectal cancer after renal transplantation Transplant Proc 35 2003 1410 1412
7. M.L. Kripe Immunoregulation of carcinogenesis: past present and future J Natl Cancer Inst 80 1998 722 727
8. M. Guba, C. Graeb, K.W. Jauch, and E.K. Geissler Pro and anti-cancer effect of immunosuppressive agents used in organ transplantation Transplantation 77 2004 1777 1782
9. H.T. Sorensen, L. Mellemkjaer, G.L. Nielsen, J.A. Baron, J.H. Olsen, and M.R. Karagas Skin cancers and non-hodgkin lymphoma among users of systemic glucocorticoids: a population-based cohort study J Natl Cancer Inst 96 2004 709 711
10. A. Trattner, E. Hodak, and M. David The appearance of Kaposi sarcoma during corticosteroid therapy Cancer 72 1993 1779 1783
11. I. Penn, W. Hammond, L. Brettschneider, and T.E. Starzl Malignant lymphomas in transplantation patients Transplant Proc 1 1969 106
12. W.W. Bottomley, G. Ford, W.J. Cunliffe, and J.A. Cotterill Aggressive squamous cell carcinomas developing in patients receiving long-term azathoprine Br J Haematol 133 1995 460
13. R.H. Williams, D.H. Lively, D.C. DeLong, J.C. Cline, and M.J. Sweeny Mycophenolic acid: antiviral and antitumor properties J Antibiot (Tokyo) 21 1968 463 464
14. K. Leckel, W.D. Beecken, D. Jonas, E. Oppermann, M.C. Coman, and K.F. Beck The immunosuppressive drug mycophenolate mofetil impairs the adhesion capacity of gastrointestinal tumour cells Clin Exp Immunol 134 2003 238 245
15. M. Herman, T. Weinstein, A. Korzets, A. Chagnac, Y. Ori, and D. Zevin Effect of cyclosporin A on DNA repair and cancer incidence in kidney transplant recipients J Lab Clin Med 137 2001 14 20
16. M. Hojo, T. Morimoto, M. Maluccio, T. Asano, K. Morimoto, and M. Lagman Cyclosporin induces cancer progression by a cell autonomous mechanism Nature 397 1999 530 534
17. M. Guba, P. von Breitenbuch, M. Steinbauer, G. Koehl, S. Flegel, and M. Hornung Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor Nat Med 8 2002 128 135
18. J. Dantal, M. Hourmant, D. Cantarovich, M. Giral, G. Blancho, and B. Dreno Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporin regimens Lancet 351 1998 623 628
19. R.P. Carroll, H.M. Ramsay, A.A. Fryer, C.M. Hawley, D.L. Nicol, and P.N. Harden Incidence and prediction of nonmelanoma skin cancer post-renal transplantation: a prospective study in Queensland, Australia Am J Kidney Dis 41 2003 676 683
20. S. Jonas, N. Rayes, U. Neumann, R. Neuhaus, W.O. Bechstein, and O. Guckelberger De novo malignancies after liver transplantation using tacrolimus-based protocols or cyclosporine-based quadruple immunosuppression with an interleukin-2 receptor antibody or antithymocyte globulin Cancer 80 1997 1141 1150
21. G. Schumacher, M. Oidtmann, S. Rosewicz, J. Langrehr, S. Jonas, and A.R. Mueller Sirolimus inhibits growth of human hepatoma cells in contrast to tacrolimus which promotes cell growth Transplant Proc 34 2002 1392 1393
22. M. Maluccio, V. Sharma, M. Lagman, S. Vyas, H. Yang, and B. Li Tacrolimus enhances transforming growth factor-beta1 expression and promotes tumor progression Transplantation 76 2003 597 602
23. F.L. Luan, R. Ding, V.K. Sharma, W.J. Chon, M. Lagman, and M. Suthanthiran Rapamycin is an effective inhibitor of human renal cancer metastasis Kidney Int 63 2003 917 926
24. G.E. Koehl, J. Andrassy, M. Guba, S. Richter, A. Kroemer, and M.N. Scherer Rapamycin protects allografts from rejection while simultaneously attacking tumors in immunosuppressed mice Transplantation 77 2004 1319 1326
25. B.D. Kahan, R. Knight, L. Schoenberg, J. Pobielski, R.H. Kerman, and K. Mahalati Ten years of sirolimus therapy for human renal transplantation: the University of Texas at Houston experience Transplant Proc 35 2003 25S 34S
26. T. Mathew, H. Kreis, and P. Friend Two-year incidence of malignancy in sirolimus-treated renal transplant recipients: results from five multicenter studies Clin Transplant 18 2004 446 449
27. J.M. Campistol, A. Gutierrez Dalmau, and J. Vicente Torregrosa Conversion to sirolimus: a successful treatment for posttransplantation Kaposi's sarcoma Transplantation 77 2004 760 762
28. I. Yokoyama, B. Carr, H. Saitsu, S. Iwatsuki, and T.E. Starzl Accelerated growth rates of recurrent hepatocellular carcinoma after liver transplantation Cancer 68 1991 2095 2100
29. R. Steininger, F. Herbst, R. Fugger, F. Muhlbacher, and A. Fritsch Immunosuppression does not enhance tumor growth after orthotopic liver transplantation for hepatoma Transplant Proc 24 1992 2690 2692
30. E. Regalia, L.R. Fassati, and U. Valente Pattern and management of recurrent hepatocellular carcinoma after liver transplantation J Hep Bil Pancr Surg 5 1998 29 34
31. S. Roayaie, J.D. Schwartz, M.W. Sung, S.H. Emre, C.M. Miller, and G.E. Gondolesi Recurrence of hepatocellular carcinoma after liver transplant: patterns and prognosis Liver Transpl 10 2004 534 540
32. H. Bismuth, L. Chiche, R. Adam, D. Castaing, T. Diamond, and A. Dennison Liver resection versus transplantation for hepatocellular carcinoma in cirrhotic patients Ann Surg 218 1993 145 151
33. V. Mazzaferro, E. Regalia, R. Doci, S. Andreola, A. Pulvirenti, and F. Bozzetti Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis N Engl J Med 334 1996 693 699
34. P. Majno, G. Mentha, E. Giostra, S. Terraz, L. Rubbia-Brandt, and T. Berney Geneva liver cancer study group. Treatment of hepatocellular carcinoma at the dawn of the third millennium: liver transplantation and its alternatives Acta Gastroenterol Belg 67 2004 206 222
35. C.E. Freise, L. Ferrell, T. Liu, N.L. Ascher, and J.P. Roberts Effect of systemic cyclosporine on tumor recurrence after liver transplantation in a model of hepatocellular carcinoma Transplantation 67 1999 510 513
36. M. Vivarelli, R. Bellusci, A. Cucchetti, G. Cavrini, N. De Ruvo, and A.A. Aden Low recurrence rate of hepatocellular carcinoma after liver transplantation: better patient selection or lower immunosuppression? Transplantation 74 2002 1746 1751
37. N.M. Kneteman, J. Oberholzer, M. Al Saghier, G.A. Meeberg, M. Blitz, and M.M. Ma Sirolimus-based immunosuppression for liver transplantation in the presence of extended criteria for hepatocellular carcinoma Liver Transpl 10 2004 1301 1311
38. M. Weber, Z. Kadry, and P.A. Clavien Low recurrence rate of hepatocellular carcinoma after liver transplantation. Better patient selection or lower immunosuppression? Transplantation 74 2002 1664 1665
39. W. Wall Hepatocellular cancer, transplantation and sirolimus Liver Transpl 10 2004 1312 1314
40. M. Elsharkawi, L. Staib, D. Henne-Bruns, and J. Mayer Complete remission of postransplant lung metastases from hepatocellular carcinoma under therapy with sirolimus and mycophenolate mofetil Transplantation 79 2005 855 857
41. H.J. Kolb, and E. Holler Adoptive immunotherapy with donor lymphocyte transfusions Curr Opin Oncol 9 1997 139 145
42. R. Childs, A. Chernoff, N. Contentin, E. Bahceci, D. Schrump, and S. Leitman Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood-stem-cell transplantation N Engl J Med 343 2000 750 758
43. L.H. Buhler, T.R. Spitzer, M. Sykes, D.H. Sachs, F.L. Delmonico, and N. Tolkoff-Rubin Induction of kidney allograft tolerance after transient lymphohematopoietic chimerism in patients with multiple myeloma and end-stage renal disease Transplantation 74 2002 1405 1409
44. Z. Kadry, B. Mullhaupt, E.L. Renner, P. Bauerfeind, U. Schanz, and B.C. Pestalozzi Living donor liver transplantation and tolerance: a potential strategy in cholangiocarcinoma Transplantation 76 2003 1003 1006
45. V. Donckier, R. Troisi, M. Toungouz, I. Colle, H. Van Vlierberghe, and C. Jacquy Donor stem cell infusion after non-myeloablative conditioning for tolerance induction to HLA mismatched adult living-donor liver graft Transpl Immunol 13 2004 139 146
46. J.C. Dunkelberg, J.F. Trotter, M. Wachs, T. Bak, M. Kugelmas, and T. Steinberg Sirolimus as primary immunosuppression in liver transplantation is not associated with hepatic artery or wound complications Liver Transpl 9 2003 463 468
47. M. Montalbano, G.W. Neff, N. Yamashiki, D. Meyer, M. Bettiol, and G. Slapak-Green A retrospective review of liver transplant patients treated with sirolimus from a single center: an analysis of sirolimus-related complications Transplantation 78 2004 264 268
48. G.W. Neff, P. Ruiz, J.R. Madariaga, S. Nishida, M. Montalbano, and D. Meyer Sirolimus-associated hepatotoxicity in liver transplantation Ann Pharmacother 38 2004 1593 1596
49. J. Bruix, and J.M. Llovet Prognostic prediction and treatment strategies in hepatocellular carcinoma Hepatology 35 2002 519 524